The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Takeda, GE Healthcare Forge Alliance for Hepatic Diseases
November 12, 2014
- Ethical Drug Sales Down 0.2% in September Owing to Long-Listed Drug Sales Decline: Crecon Report
November 12, 2014
- BIKEN Begins Clinical Trial of Varicella Vaccine for Herpes Zoster
November 12, 2014
- Dermatology Firm Maruho Eyes US Product Rollout in Next 3 Years
November 12, 2014
- Santen Extending Geographic Reach in Europe after Merck Asset Transfer
November 11, 2014
- Kowa Looks to Triple Eye Drug Business with Glanatec
November 11, 2014
- Germany Designates Eisai’s Antiepileptic Drug Fycompa as Reference Price Drug
November 11, 2014
- AstraZeneca Taps Foreign Doctors to Speak on Forxiga Use Abroad
November 11, 2014
- Nichi-Iko Aims for 300 Million Yen Second Half Sales for Generics Launched in December
November 10, 2014
- Takeda Files Suit in US Claiming Infringement of Its Patents for Gout Treatment Colcrys
November 10, 2014
- MTPC, J&J Collaborate to Promote Educational Activities for Diabetes
November 10, 2014
- Feburic Grabs Top Slot for GP Market in September “Mind Share” Ranking
November 10, 2014
- Meiji Seika Pharma Poised to Get Lion’s Share in Antidepressant Market
November 10, 2014
- Bayer, Kyoto Univ. to Hold First Collaborative Meeting by March
November 7, 2014
- Sales of Four Major Wholesalers Hit by Drop in Long-Listed Product Sales
November 7, 2014
- Ono to Copromote Opdivo with Bristol-Myers in Japan: President
November 7, 2014
- Trebananib Fails to Demonstrate Improvement in OS in PIII Study for Recurrent Ovarian Cancer: Takeda
November 7, 2014
- Toray Medical Files Nalfurafine for Pruritus Associated with Chronic Hepatic Disease
November 7, 2014
- Daiichi Sankyo to Cut Japan Jobs to Brace for Olmetec Patent Expiry
November 6, 2014
- Lorcaserin Confirms POC as Potential Smoking Cessation Aid in PII Study in US: Eisai
November 6, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…